The effect of AL0671, a novel potassium channel opener, on potassium current in rat aortic smooth muscle cells. 1995

S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
Basic Research Laboratories, Green Cross Corporation, Osaka, Japan.

1. We evaluated the mechanism of activation by AL0671, a novel potassium channel opener, of potassium current in rat aortic smooth muscle cells. 2. Under conditions of whole cell recording, AL0671 (1-1000 microM) markedly increased potassium current with a Hill coefficient of 2 and dissociation constant of 1.5 x 10(-4) M. This activation was completely inhibited by intracellular ATP. 3. Under inside-out patch conditions, the ATP-sensitive K+ channels (KATP) treated with AL0671 (100 microM) showed prolongation of the slower open time component and shortening of the slower closed time component without modification of channel conductance.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D001011 Aorta The main trunk of the systemic arteries. Aortas
D001643 Bridged Bicyclo Compounds Saturated alicyclic hydrocarbon molecules consisting of two rings that have two non-adjacent atoms in common. Bicyclo Compounds,Bicyclo Compounds, Bridged

Related Publications

S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
November 1993, British journal of pharmacology,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
June 2003, Planta medica,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
February 2004, Planta medica,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
November 1996, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
January 2015, The journal of sexual medicine,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
March 2005, European journal of pharmacology,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
November 1995, The Journal of urology,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
September 2007, Basic & clinical pharmacology & toxicology,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
January 1992, Pharmacology,
S Matzno, and R Sato, and H Takai, and Y Aida, and S Karasaki, and M Oyaizu, and N Nakamura, and R Katori
January 2012, Journal of pharmacology & pharmacotherapeutics,
Copied contents to your clipboard!